Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc  

(Public, LON:AZN)   Watch this stock  
Find more results forAZN
-10.00 (-0.20%)
Jan 18 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,938.50 - 5,015.00
52 week 4,136.50 - 5,520.00
Open 5,004.00
Vol / Avg. 1.57M/1.61M
Mkt cap 62,909.36M*
P/E 24.62
Div/yield 68.90*
EPS 2.02*
Shares 1,266.22M
Beta     -
Inst. own     -
Feb 2, 2018
Full Year 2017 AstraZeneca PLC Earnings Release - 7:00am GMT - Add to calendar
Jan 9, 2018
AstraZeneca PLC at SEB Nordic Seminar
Dec 14, 2017
AstraZeneca PLC Investor Science Event Late-Stage Pipeline Corporate Call - Webcast
Dec 7, 2017
AstraZeneca PLC at Berenberg European Conference
Dec 1, 2017
AstraZeneca PLC at Societe Generale Premium Review Conference
Nov 30, 2017
AstraZeneca PLC at Deutsche Bank dbAccess Pharmaceutical & Healthcare Corporate day
Nov 29, 2017
AstraZeneca PLC at Piper Jaffray Healthcare Conference
Nov 9, 2017
Q3 2017 AstraZeneca PLC Earnings Call
Nov 9, 2017
Q3 2017 AstraZeneca PLC Earnings Release

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 10.41% 14.81%
Operating margin 18.44% 21.31%
EBITD margin - 30.92%
Return on average assets 4.01% 5.56%
Return on average equity 20.10% 20.99%
Employees 59,700 -
CDP Score - A


1 Francis Crick Avenue Cambridge Biomedical Campus
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Officers and directors

Pascal Soriot Executive Director and Chief Executive Officer
Age: 57
Marc Dunoyer Executive Director, Chief Financial Officer
Age: 64
Fiona Cicconi Executive Vice-President, Human Resources
Sean Bohen M.D., Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Pam P. Cheng Executive Vice President - Operations and Information Technology
Age: 45
Ruud Dobber Executive Vice President, North America
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Mark Mallon Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
Menelas Pangalos Executive Vice President - IMED Biotech Unit and Global Business Development
Leon Wang Executive Vice President - Asia Pacific